View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
August 11, 2022updated 13 Sep 2022 2:45pm

Psoriasis accounts for 17.2% share of global Immunology clinical trial activity in 2021

By Carmen

Psoriasis accounted for a 17.2% share of the global clinical trials within the Immunology therapy area in 2021, registering an increase of 1.7% when compared with the last ten-year average of 15.5% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials for Psoriasis

Industry sponsored trials held a 70.4% share of all the clinical trials for Psoriasis indication in 2021, registering a decrease of 0.5% when compared with the ten-year average of 70.9%. Non-industry sponsored trials accounted for a 29.6% share in 2021, registering an increase of 0.5% over the ten-year average of 29.1%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Psoriasis trials

Asia-Pacific was the top region for industry sponsored Psoriasis trials, accounting for a 58.0% share in 2021, when compared with the five-year average of 40.1% and ten-year average of 34.0%.

North America was at the second position with a 32.8% share in 2021, over the five-year average of 44.4% and ten-year average of 48.3%, followed by Europe with a 30.3% share in 2021, as against five-year and ten-year averages of 44.4% and 45.9% respectively.

Middle East and Africa stood fourth with a 4.2% share in 2021, compared with the five-year average of 5.0% and ten-year average of 5.7%, followed by South and Central America with a 4.2% share in 2021, over five-year and ten-year averages of 4.9% and 5.5% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Psoriasis trials, accounting for a 32.8% share in 2021, as against the five-year average of 14.2% and ten-year average of 7.8%.

The US held a 31.9% share in 2021, over the five-year average of 41.1% and ten-year average of 44.4%, followed by Poland with a 15.1% share in 2021, compared with the five-year and ten-year averages of 14.8% and 13.8% respectively.

Canada held an 11.8% share in 2021, as against the five-year average of 18.4% and ten-year average of 19.6%.

Germany held an 11.8% share in 2021, over the five-year and ten-year averages of 22.9% and 24.9% respectively.

Top regions of non-industry sponsored Psoriasis trials

Asia-Pacific was the top region for non-industry sponsored Psoriasis trials, accounting for a 58.5% share in 2021 when compared with the five-year average of 53.8% and ten-year average of 50.0%.

Middle East and Africa was at the second position with a 15.1% share in 2021, over the five-year and ten-year averages of 12.2% and 11.5% respectively, followed by North America with a 13.2% share in 2021, as against the five-year average of 12.9% and ten-year average of 16.0%.

Europe stood at the fourth position with an 11.3% share in 2021, compared with the five-year average of 21.1% and ten-year average of 21.5%, followed by South and Central America with a 1.9% share in 2021, over the five-year and ten-year averages of 0.0% and 1.0% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Psoriasis trials, accounting for a 45.3% share in 2021, as against the five-year average of 23.7% and ten-year average of 20.6%.

The US held a 13.2% share in 2021, over the five-year average of 12.9% and ten-year average of 15.7%, followed by Iran with a 9.4% share, compared with the five-year and ten-year averages of 11.0% and 9.6% respectively.

Thailand held a 5.7% share in 2021, as against the five-year average of 3.3% and ten-year average of 1.9%.

India held a 5.7% share in 2021, over the five-year average of 22.0% and ten-year average of 16.2%.

Phase I trials lead industry sponsored clinical trials for Psoriasis in 2021

Phase I trials held a 45.9% share of industry sponsored clinical trials for Psoriasis in 2021, over the five-year average of 39.0% and ten-year average of 36.7%.

Phase II trials held a 20.3% share in 2021, as against the five-year average of 22.2% and ten-year average of 23.4%. Phase III trials held a 20.3% share in 2021, compared with the five-year and ten-year averages of 23.1% and 26.2% respectively.

Phase IV trials held a 13.5% share in 2021, over the five-year average of 15.7% and ten-year average of 13.8%.

Phase II trials lead non-industry sponsored clinical trials for Psoriasis in 2021

Phase II trials held a 37.5% share of non-industry sponsored clinical trials for Psoriasis in 2021, over the five-year average of 40.9% and ten-year average of 41.5%.

Phase IV trials held a 35.7% share in 2021, as against the five-year average of 35.2% and ten-year average of 37.7%. Phase I trials held a 16.1% share, compared with the five-year and ten-year averages of 9.2% and 7.6% respectively.

Phase III trials held a 10.7% share in 2021, over the five-year average of 14.7% and ten-year average of 13.2%.

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena